Comparative Pharmacology
Head-to-head clinical analysis: ACIPHEX SPRINKLE versus PRILOSEC OTC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACIPHEX SPRINKLE versus PRILOSEC OTC.
ACIPHEX SPRINKLE vs PRILOSEC OTC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rabeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, suppressing gastric acid secretion.
20 mg orally once daily as delayed-release capsules; maximum dose 40 mg per day.
20 mg orally once daily for 14 days for frequent heartburn; may repeat 14-day course every 4 months.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in healthy subjects; prolonged in CYP2C19 poor metabolizers (up to 3-4 hours). Clinically, the short half-life results in rapid clearance but sustained acid suppression due to irreversible binding to the proton pump.
Approximately 0.5–1 hour in healthy subjects; longer (up to 3 hours) in slow metabolizers or hepatic impairment. Clinically, the duration of acid suppression exceeds the half-life due to accumulation in parietal cell canaliculi.
Primarily hepatic metabolism (CYP2C19 and CYP3A4); <1% excreted unchanged in urine; approximately 90% of the dose excreted as metabolites in urine and feces via biliary elimination.
Primarily hepatic metabolism; about 80% of metabolites are excreted in urine, and the remainder in feces via bile. Less than 1% of unchanged drug is excreted in urine.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor